Trial Date Set For Seroquel Patent Litigation
LONDON, March 12, 2008-AstraZeneca today announced a trial date
has been set for patent litigation in the US District Court for the
District of New Jersey against Teva Pharmaceutical Industries Ltd.
and Sandoz, Inc. alleging infringement of AstraZeneca’s
patent as a result of Teva’s and Sandoz’s filings of
Abbreviated New Drug Applications (ANDAs). The ANDAs seek approval
to market generic versions of SEROQUEL® (quetiapine fumarate
tablets) in the US before SEROQUEL’s patent expires in 2011.
The Court has set a date for trial beginning on 11 August
AstraZeneca is a major international healthcare business engaged in the research, development, manufacture and marketing of prescription pharmaceuticals and the supply of healthcare services. It is one of the world's leading pharmaceutical companies with healthcare sales of $29.55 billion and leading positions in sales of gastrointestinal, cardiovascular, neuroscience, respiratory, oncology and infection products. AstraZeneca is listed in the Dow Jones Sustainability Index (Global) as well as the FTSE4Good Index.
For more information about AstraZeneca please visit: www.astrazeneca.com
For further information:
Neil McCrae, +44 207 304 5045 (24 hours)
Steve Brown, +44 207 304 5033 (24 hours)
Chris Sampson, +44 207 304 5130 (24 hours)
Jonathan Hunt, +44 207 304 5087
Ed Seage, +1 302 886 4065
Karl Hard, +44 207 304 5322
Jorgen Winroth, +1 212 579 0506
Mina Blair, +44 20 7304 5084
Peter Vozzo, (MedImmune) +1 301 398 4358
Posted: March 2008